Retention in Care among Patients with Early HIV Disease in Haiti

In September 2015, the World Health Organization updated their guidelines to recommend antiretroviral therapy (ART) for all people living with HIV. Countries are now in the process of implementing strategies to provide universal HIV treatment. We analyzed the rate of retention and time to ART eligibility (according to 2013 WHO guidelines) among 3,345 adult patients receiving positive HIV test results between February 1, 2003 and March 31, 2013 at the GHESKIO Clinic in Haiti, with WHO stage 1 or 2 disease and initial CD4 cell count >500 cells/mm3. Among the 3,345 patients, 2,423 (72%) were female, the median age was 33 years, 3,089 (92%) lived in Port-au-Prince, and 1,944 (58%) had attended no school or primary school only. The median initial CD4 cell count was 668 cells/mm3 (IQR: 572-834); over the subsequent 2 years, 1,485 patients (44%) were lost to follow-up and 7 (<1%) died pre-ART, 1,041 (31%) were retained in pre-ART care, and 819 (24%) initiated ART. In multivariate analysis, secondary education (aOR 1.27; 95% CI: 1.10-1.47), female gender (aOR: 1.28; 95% CI: 1.09-1.50), co-habitation (aOR: 1.31; 95% CI: 1.09-1.57), and residence in Port-au-Prince (aOR: 1.43; 95% CI: 1.09-1.88) were associated with retention in care. The median time from baseline CD4 count to ART eligibility was 1.7 years. Prior to the implementation of universal treatment, pre-ART attrition was high among patients who did not qualify for ART at presentation. Though implementing WHO recommendations for universal ART will require service expansion, it will likely result in improved retention for those at risk of being lost to follow-up.

[1]  B. Williams,et al.  CD4 Cell Count: Declining Value for Antiretroviral Therapy Eligibility. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  C. Fraser,et al.  CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time. , 2015 .

[3]  R. Brookmeyer,et al.  Simplified HIV Testing and Treatment in China: Analysis of Mortality Rates Before and After a Structural Intervention , 2015, PLoS medicine.

[4]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[5]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[6]  P. Farmer,et al.  Factors Impacting the Provision of Antiretroviral Therapy to People Living with HIV: The View from Haiti , 2014, Antiviral therapy.

[7]  J. Pape,et al.  The Haiti Research-Based Model of International Public Health Collaboration: The GHESKIO Centers , 2014, Journal of acquired immune deficiency syndromes.

[8]  M. Bassett,et al.  WHO's new guidelines for antiretroviral treatment , 2013, The Lancet.

[9]  Anne M Johnson,et al.  Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Lei Wang,et al.  Prevention of HIV-1 infection with early antiretroviral therapy. , 2011, The New England journal of medicine.

[11]  S. Rosen,et al.  Retention in HIV Care between Testing and Treatment in Sub-Saharan Africa: A Systematic Review , 2011, PLoS medicine.

[12]  Till Bärnighausen,et al.  Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. , 2014, The Lancet. Global health.